Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin C  COVID-19 treatment studies for Vitamin C  C19 studies: Vitamin C  Vitamin C   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Recovery time 15% Improvement Relative Risk Recovery time (b) 15% Time to viral- 14% Time to viral- (b) 19% c19early.com/c Yang et al. Vitamin C for COVID-19 RCT LATE TREATMENT Favors high dose Favors low dose
Yang, 20 patient vitamin C late treatment RCT: 15% faster recovery [p=0.15] and 14% faster viral clearance [p=0.25] https://c19p.org/yang2
copied to clipboard
Traditional Chinese medicine together with high-dose vitamin C improves the therapeutic effect of western medicine against COVID-19
Yang et al., Am. J. Transl. Res., 14:1
15 Jan 2022    Source   PDF   Share   Tweet
Prospective study of 60 patients in China with three arms: SOC, SOC+TCM, and SOC+TCM+high dose vitamin C, showing successively faster recovery with the addition of TCM and the addition of high dose vitamin C. TCM included low dose vitamin C. ChiCTR2000032717. IV vitamin C 10g/60kg twice a day, and oral vitamin C 3g three times a day.
recovery time, 15.4% lower, relative time 0.85, p = 0.15, treatment mean 13.45 (±3.11) n=10, control mean 15.89 (±4.06) n=10, severe patients, group C vs. group B.
recovery time, 14.6% lower, relative time 0.85, p = 0.02, treatment mean 7.0 (±0.94) n=10, control mean 8.2 (±1.14) n=10, non-severe patients, group C vs. group B.
time to viral-, 14.2% lower, relative time 0.86, p = 0.25, treatment mean 9.7 (±1.49) n=10, control mean 11.3 (±4.03) n=10, severe patients, group C vs. group B.
time to viral-, 19.0% lower, relative time 0.81, p = 0.02, treatment mean 5.1 (±0.95) n=10, control mean 6.3 (±1.06) n=10, non-severe patients, group C vs. group B.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Yang et al., 15 Jan 2022, Randomized Controlled Trial, China, peer-reviewed, 11 authors, study period 1 February, 2020 - 29 February, 2020.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin CAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit